Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

Study Overview

• Status: Completed
• Conditions: Melanoma; Lymphoma; Head and Neck Cancer; Gastric Cancer; Ovarian Cancer; Hepatocellular Carcinoma (HCC); Lung Cancer; Bladder Cancer; Endometrial Cancer; Solid Tumors; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC); UC (Urothelial Cancer); Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
• Intervention / Treatment: Drug: MK-3475; Drug: INCB024360

• Study Type: Interventional
• Enrollment (Actual): 444
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • La Jolla, California, United States, 92093
      • UC San Diego Moores Cancer Center
    • Los Angeles, California, United States, 90025
      • The Angeles Clinic and Research Institute
    • Sacramento, California, United States, 95817
      • US Davis Cancer Center
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Cancer Center
  • Connecticut
    • Farmington, Connecticut, United States, 06030-1601
      • University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center
  • Florida
    • Miami, Florida, United States, 33176
      • Miami Cancer Institute at Baptist Health, Inc
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute
  • Illinois
    • Chicago, Illinois, United States, 60637
      • The University of Chicago Medicine
  • Kansas
    • Topeka, Kansas, United States, 66618
      • St. Francis Cancer Center
  • Maryland
    • Baltimore, Maryland, United States, 21204
      • Greater Baltimore Cancer Center
    • Baltimore, Maryland, United States, 21229
      • St. Agnes Hospital Cancer Institute
    • Bethesda, Maryland, United States, 20817
      • The Center for Cancer and Blood Disorders (RCCA MD LLC- Maryland Division)
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Hospital and Health Systems
  • Minnesota
    • Saint Louis Park, Minnesota, United States, 55426
      • Health Partners Institute
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Hackensack University Medical Center - John Theurer Cancer Center
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • The Christ Hospital Hematology Oncology, Lindner Research Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19111-2497
      • Fox Chase Cancer Center
    • Philadelphia, Pennsylvania, United States, 19104
      • University of Pennsylvania Hospital
    • Pittsburgh, Pennsylvania, United States, 15232
      • University of Pittsburgh Medical Center Hillman Cancer Center
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Greenville Health System Cancer Institute
  • Tennessee
    • Germantown, Tennessee, United States, 38120
      • West Cancer Center
    • Nashville, Tennessee, United States, 37203-2173
      • Sarah Cannon Research Institute at Tennessee Oncology
  • Texas
    • Dallas, Texas, United States, 75390
      • University Of Texas Southwestern Medical Center At Dallas
  • Virginia
    • Arlington, Virginia, United States, 22031
      • Virginia Cancer Specialists

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects with histologically or cytologically non-small cell lung cancer (NSCLC), melanoma, transitional cell carcinoma of the genitourinary (GU) tract, renal cell cancer, triple negative breast cancer, adenocarcinoma of the endometrium or squamous cell carcinoma of the head and neck (Phase 1).
• Subjects with histologically confirmed melanoma, NSCLC, transitional cell carcinoma of the GU tract, TNBC, SCCHN, ovarian cancer, MSI high colorectal cancer (CRC), RCC, gastric cancer, HCC and DLBCL (Phase 2).
• Life expectancy > 12 weeks.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
• Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.
• Laboratory and medical history parameters within protocol-defined range.
• For Phase 1: Subjects who have advanced or metastatic disease as noted above that have received at least one prior therapy or have advanced or metastatic disease for which no curative treatment is available may be enrolled.

• For Phase 2 expansion cohorts: Subjects with NSCLC, melanoma (checkpoint inhibitor naïve, primary refractory melanoma, relapsed melanoma), transitional cell carcinoma of the GU tract, SCCHN, ovarian cancer, MSI high CRC, RCC, DLBCL, TNBC, gastric cancer, and HCC.

  • Phase 2 expansion: NSCLC

    • Subjects who have received at least 1 prior platinum-based therapy. Subjects who have a non-platinum-based regimen may be enrolled with medical monitor approval.
    • Tumors with epidermal growth factor receptor mutation positive or anaplastic lymphoma kinase fusion oncogene positive treated with a tyrosine kinase inhibitor are permitted; however, subjects should have progressed on or be intolerant to the targeted therapy.
    • Subjects must not have received immunotherapy with programmed death receptor-1 (PD-1) or cytotoxic T-lymphocyte antigen (CTLA-4) targeted therapy.

  • Phase 2 expansion: Melanoma

    • Documentation of V600E-activating BRAF mutation status.
    • Prior systemic therapy requirements.
    • Melanoma immune checkpoint-naïve: Subjects must not have received immunotherapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy. Exception: Prior anti-CTLA-4 in the adjuvant setting would be permitted.
    • Primary refractory melanoma: Subjects must have received prior treatment with anti-PD-1 or anti-PD-L1 therapy (alone or as part of a combination) in the advanced or metastatic setting and have progressive disease as their best response to treatment that is confirmed 4 weeks later.
    • Relapsed melanoma: Subjects must have received prior anti-PD-1 or anti-PD-L1 therapy (alone or as part of a combination) in the advanced or metastatic setting and achieved partial response ore complete response but later have confirmed progressive disease.
    • Subjects enrolling in the primary refractory or relapsed melanoma must be willing to undergo mandatory pretreatment and on-treatment biopsies.
    • Ocular melanoma is excluded.

  • Phase 2 expansion: Transitional cell carcinoma of the GU tract

    • Metastatic or locally advanced and not amenable to curative therapy with disease progression on or after platinum-based chemotherapy or alternative therapy if platinum-based therapy is not appropriate.
    • Prior PD-1 or CTLA-4 targeted therapies are excluded

  • Phase 2 expansion: SCCHN

    • Histologically confirmed metastatic or recurrent squamous cell carcinoma not amenable to local therapy with curative intent (surgery or radiation with or without chemotherapy). Carcinoma of the nasopharynx, salivary gland, or * *Subjects must have received at least 1 prior systemic chemotherapy regimen that must have included a platinum-based therapy.
    • Prior PD-1 or CTLA-4 targeted therapies are excluded.

  • Phase 2 expansion: Ovarian cancer

    • Subjects with FIGO Stage Ic, Stage II, Stage III, Stage IV, recurrent, or persistent (unresectable) histologically confirmed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube carcinoma.
    • Subjects must have received a platinum-taxane-based regimen as first-line therapy.
    • Prior PD-1 or CTLA-4 targeted therapies are excluded.
    • Borderline, low-malignant-potential epithelial carcinoma per histopathology is excluded.

  • Phase 2 expansion: Relapsed or refractory DLBCL

    • Prior allogeneic stem-cell transplantation is excluded.
    • Must have received > or = 1 prior treatment regimen.
    • Not a candidate for curative therapy or hematopoietic stem-cell transplantation (either due to disease burden, fitness, or preference).
    • Prior PD-1 or CTLA-4 targeted therapies are excluded.

  • Phase 2 expansion: TNBC

    • Histologically confirmed breast adenocarcinoma that is unresectable loco regional, or metastatic
    • Pathologically confirmed as triple negative, source documented, defined as both of the following:
    • Estrogen receptor (ER) and progesterone receptor (PgR) negative.
    • Human epidermal growth factor receptor 2 (HER2) negative as per American Society of Clinical Oncology/College of American Pathologists guidelines.
    • Subject must have received at least 1 prior systemic regimen for advanced or metastatic disease
    • Prior PD-1 or CTLA-4 targeted therapies are excluded.

  • Phase 2 expansion: RCC

    • Subjects with histological or cytological confirmation of clear cell RCC.
    • Not curable by surgery.
    • Subjects must have received prior antiangiogenic therapy.
    • Subjects must not have received prior immunotherapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy.

  • Phase 2 expansion: MSI high CRC

    • Subjects with histological confirmation of locally advanced unresectable or metastatic MSI high CRC.
    • MSI status is, respectively, determined by examining CRC tumor.
    • Subjects may have received no more than 2 lines of prior therapy for advanced disease.

  • Phase 2 expansion: Gastric Cancer

    • Must have histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.
    • Must have progression on or after therapy containing platinum/fluoropyrimidine or refused standard therapy.
    • Subjects may have received no more than 2 lines of prior therapy for advanced disease.
    • Prior PD-1 or CTLA-4 targeted therapies are excluded.

  • Phase 2 expansion: HCC

    • Must have histologically or cytologically confirmed diagnosis of HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible).
    • Barcelona Clinic Liver Cancer (BCLC) Stage C disease (Llovet et al 1999), or BCLC Stage B disease.
    • Subjects may have received no more than 2 lines of prior therapy for the advanced disease
    • Must have progressed on, refused, or were intolerant of sorafenib.
    • The following are excluded: Subjects with liver transplants, clear invasion of the bile duct or main portal branch(es), or hepatorenal syndrome, or subjects who have required esophageal variceal ablation within 28 days of starting study treatment.
    • Prior PD-1 or CTLA-4 targeted therapies are excluded.
  • Tumor biopsies are required. If a subject has inaccessible lesions, such as in ovarian cancer, HCC, or gastric cancer, or highly vascular lesions, such as RCC, enrollment may be considered with medical monitor approval, and archived tissue may be acceptable.
  • Females of child-bearing potential and males who use adequate birth control through 120 days post dose.

Exclusion Criteria:

• Subjects who participated in any other study in which receipt of an investigational study drug or device occurred within 2 weeks or 5 half-lives (whichever is longer) prior to first dose.
• Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). Exception: Prior anti-CTLA-4 in the adjuvant setting for subjects with melanoma would be permitted.
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable.
• Has an active autoimmune disease.
• Has evidence of noninfectious pneumonitis that required steroids or current pneumonitis.
• Live vaccine use within 30 days of first dose of study medication.
• Monoamine oxidase inhibitors.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1: MK-3475 + INCB024360; Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined	Drug: MK-3475; IV infusion; Drug: INCB024360; Oral daily dosing
Experimental: Phase 2: MK-3475 + INCB024360; (recommended phase 2 dose)	Drug: MK-3475; IV infusion; Drug: INCB024360; Oral daily dosing

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events	An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after a participant provides informed consent. A TEAE is any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Serious adverse event (SAE) is defined as an event that meets 1 of the following criteria: is fatal or life threatening, results in persistent or significant disability or incapacity, constitutes a congenital anomaly or birth defect, is clinically meaningful (i.e. defined as an event that jeopardizes the participant or requires potential medical or surgical intervention to prevent 1 of the outcomes listed above) or requires inpatient hospitalization or prolongation of existing hospitalization.	Approximately 54 months
Phase 2: Objective Response Rate (ORR)	ORR was percentage of participants with best overall response [complete response (CR) or partial response (PR)], per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Approximately 54 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 2: Duration of Response (DOR)	Duration of response is the time from the first overall response contributing to an objective response (complete or partial response) for DLBCL to the date of death or the date of first overall response of progressive diseasemeasured (by irRECIST for solid tumors or the Lugano Classification, whichever is earliest.	Up to 54 months
Phase 2: Progression Free Survival (PFS)	Progression-free survival is defined as number of days from the first day of taking study drug to the earlier of death or disease progression by irRECIST v1.1 for select solid tumors and modified Lugano Classification for DLBCL.	Up to 54 months
Phase 2: Duration of Disease Control	The duration of disease control is the time from the treatment start date to the first objective response of PD (by irRECIST v1.1 or Lugano Classification), death, or last tumor assessment date (if PD/death not present), for subjects with best overall response of SD or better.	Up to 54 months
Phase 2: Overall Survival (OS)	Overall survival is determined from the date of first dose until death due to any cause.	Up to 54 months
Phase 2: Ordinal Categorical Response Score	Ordinal categorical response score, determined by radiographic disease assessments per irRECIST v1.1. The 5-category ordinal response endpoint is determined at a given timepoint by classifying response into one of the following groups: 1 = Complete response per irRECIST v1.1 2 = Very good response, defined as > 60% tumor reduction 3 = Minor response, defined as > 30% to ≤ 60% tumor reduction 4 = Stable disease per irRECIST v1.1 5 = Progressive disease per irRECIST v1.1	Up to 54 months
Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events		Up to 54 months

Collaborators and Investigators

• Sponsor: Incyte Corporation
• Collaborators: Merck Sharp & Dohme LLC

Study record dates

Study Major Dates

• Study Start (Actual): July 17, 2014
• Primary Completion (Actual): November 26, 2018
• Study Completion (Actual): November 6, 2020

Study Registration Dates

• First Submitted: June 26, 2014
• First Submitted That Met QC Criteria: June 27, 2014
• First Posted (Estimate): July 1, 2014

Study Record Updates

• Last Update Posted (Actual): February 14, 2022
• Last Update Submitted That Met QC Criteria: February 11, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Skin Diseases; Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Diseases; Breast Diseases; Kidney Neoplasms; Breast Neoplasms; Genomic Instability; Carcinoma, Renal Cell; Carcinoma; Endometrial Neoplasms; Triple Negative Breast Neoplasms; Microsatellite Instability; Antineoplastic Agents; Antineoplastic Agents, Immunological; Pembrolizumab
• Other Study ID Numbers: INCB 24360-202/ ECHO-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No